Theorem Clinical Research

Soligenix

Soligenix awarded $24.7M NIAID contract for heat stable RiVax vaccine

Friday, September 26, 2014 03:05 PM

Soligenix, a Princeton, N.J.-based late-stage biopharmaceutical company developing products that address unmet medical needs in inflammation, oncology and biodefense, has been awarded a contract valued at up to $24.7 million inclusive of options by the U.S. Department of Health and Human Service's NIH, specifically funded by the National Institute of Allergy and Infectious Diseases (NIAID). The objectives of the contract are to advance the development of Soligenix's thermostabilization technology, ThermoVax, combined with the company's ricin toxin vaccine, Rivax, as a medical countermeasure (MCM) to prevent the effects of ricin exposure.

More... »


Soligenix recieves $300,000 NIAID SBIR grant award for Melioidosis

Friday, February 14, 2014 01:46 PM

Soligenix, a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, has been awarded a Small Business Innovation Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID), to support further preclinical development of SGX943 as a treatment for melioidosis. The award will provide Soligenix with approximately $300,000 over one year to conduct the studies in collaboration with Tulane University.

More... »


Soligenix appoints Richard Straube chief medical officer

Tuesday, January 7, 2014 08:00 AM

Soligenix, a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, has appointed Richard Straube, M.D., as its senior vice president and chief medical officer.

More... »

Soligenix awarded NIAID contract

Wednesday, October 2, 2013 01:14 PM

Soligenix, a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense medical countermeasures (MCMs) for which there remains an unmet medical need, has been awarded a contract valued at up to $6.4 million by the U.S. Department of Health and Human Service's NIH (specifically funded by the National Institute of Allergy and Infectious Diseases or NIAID).

More... »

Soligenix, SciClone collaborate in personalized medicine

Monday, July 8, 2013 12:00 PM

Soligenix, a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense countermeasures where there is an unmet medical need, has announced a personalized medicine collaboration with SciClone Pharmaceuticals in the company's oral mucositis clinical program with SGX942. Soligenix will receive access to SciClone's oral mucositis clinical and regulatory data library in exchange for commercialization rights in China, including Hong Kong and Macau.

More... »

Soligenix completes phase I in SGX203 for pediatric Crohn’s

Wednesday, July 3, 2013 08:50 AM

Soligenix, a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense countermeasures where there remains an unmet medical need, has enrolled and treated all patients in the phase I study BDP-PCD-01, a clinical study for development of SGX203 (oral beclomethasone 17,21-dipropionate or oral BDP) for the treatment of pediatric Crohn's disease. The SGX203 development program previously has received Fast Track and Orphan Drug designations from the FDA.

More... »

Soligenix initiates phase 1 study of SGX203 for pediatric Crohn's disease

Thursday, May 16, 2013 08:00 AM

Soligenix, a clinical stage biopharmaceutical company focused on inflammatory diseases and biodefense countermeasures, has initiated the first clinical study for development of SGX203 (oral beclomethasone 17, 21-dipropionate or oral BDP) for the treatment of pediatric Crohn's disease. The program has previously received Fast Track and Orphan Drug designations from the FDA for oral BDP as a treatment for pediatric Crohn's disease.

More... »

Soligenix, Intrexon pursue melioidosis therapy through exclusive collaboration

Friday, May 3, 2013 10:48 AM

Soligenix, a clinical stage biopharmaceutical company focused on inflammatory diseases and biodefense countermeasures, will jointly develop a treatment for melioidosis through a worldwide exclusive collaboration with Intrexon, a synthetic biology company that utilizes its proprietary technologies to provide control over cellular function.

More... »

Soligenix receives IND clearance from FDA for SGX942 in oral mucositis

Wednesday, March 27, 2013 08:59 AM

The FDA cleared the Soligenix’s Investigational New Drug (IND) application for SGX942 for the treatment of oral mucositis resulting from radiation and/or chemotherapy treatment in head and neck cancer patients.

More... »

FDA grants Soligenix Fast Track for OrbeShield for gastrointestinal acute radiation syndrome

Thursday, January 31, 2013 02:00 PM

Soligenix, a development-stage biopharmaceutical company, announced today that its OrbeShield (oral beclomethasone 17, 21-dipropionate or oral BDP) development program for the treatment of gastrointestinal acute radiation syndrome (GI ARS) has received Fast Track designation from the FDA.

More... »

CenterWatch Data Library
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

October 27

NIH’s I-Corps boot camp aims to transform researchers into better businesspeople before they launch products

Covance, Frenova form partnership to share patient databases, find effective treatments for renal disease

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

CROs driving changes in patient recruitment
Data- and tech-aided enrollment services a competitive advantage

Trials with in-home nurses poised to grow
Higher expense, but may improve recruitment and retention for select trials

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Today's fastest, most economical sponsors
Standout sponsors reveal how they shorten regulatory, clinical cycle times

From the trenches: Sites' eye view of state of the industry
CW’s first site focus groups uncover frustration with 'progress,' but a passion for their mission

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs